Moderna offers to sell booster shots from January; indemnity-waiver talks on

New Delhi: US vaccine maker Moderna has offered to sell booster doses of its Covid vaccine to India, from January 2022 even as the government continues to hold negotiations with Moderna and J&J on the indemnity waiver.

At present, the talks involve the sale of almost 200 million doses. They include 50 million from Pfizer, 70 million from J&J (since J&J has a single-dose vaccine, that translates to vaccines for 140 million people) and another 50 million from Moderna.

The discussions, however, point to the supply of vaccines at a future date, which would mean that the shots may have little impact on India’s budget for anti-Covid shots that is currently estimated at Rs 45,000-50,000 crore.

The latest US offer that envisages around 8 crore shots for India would also be useful if it is delivered soon as domestic production is expected to rise steadily from August. The MEA spokesperson said he is still awaiting details of how many vaccines would be donated by the US in the first tranche of 25 million.

According to US officials, these would be either Pfizer, Moderna or J&J. The MEA official said that Bharat Biotech had sought emergency use listing (EUL) from the WHO for Covaxin, as has the Russian vaccine maker of Sputnik.

Questioned about Indians who had been vaccinated with Covaxin are reportedly facing hurdles in foreign countries, the spokesperson said the ministry “was working to protect the interests of Indians abroad. We’re taking up the issue with concerned governments.”

  • Related Posts

    • Pharma
    • December 23, 2024
    • 45 views
    Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

    India’s healthcare and pharmaceutical sectors raised Rs 14,811 crore through initial public offerings (IPOs) in 2024, the largest since 2019, driven by strong domestic demand amid expanding global opportunities. According…

    • Pharma
    • December 23, 2024
    • 72 views
    NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

    The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 65 new drug formulations and notified ceiling price fixation of 13 formulations. The regulatory body, under the Department of…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

    Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

    NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

    NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

    India-Latin America trade and collaboration prospects discussed at Kerala University conference

    India-Latin America trade and collaboration prospects discussed at Kerala University conference

    Karnataka Govt Files Criminal Cases Against Pharma Firm In Ballari Maternal Deaths Case

    Karnataka Govt Files Criminal Cases Against Pharma Firm In Ballari Maternal Deaths Case

    NPPA Notifies Ceiling Price Of 13 Formulations, Retail Price Of 65 New Drugs

    NPPA Notifies Ceiling Price Of 13 Formulations, Retail Price Of 65 New Drugs

    Over 14,000 PMBJK Centres Set Up To Provide Generic Medicines: Govt

    Over 14,000 PMBJK Centres Set Up To Provide Generic Medicines: Govt